IGN AMP001
Alternative Names: IGN-AMP001Latest Information Update: 16 Sep 2021
At a glance
- Originator IntegoGen
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hidradenitis suppurativa
Most Recent Events
- 08 Sep 2021 IntegoGen withdrawn a phase I clinical trial prior to enrollment in Hidradenitis suppurativa as trial did not proceed to FDA submission (NCT04541550)
- 09 Sep 2020 Preclinical trials in Hidradenitis suppurativa in USA (Parenteral) prior to September 2020